PARP9 Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via STAT1/IRF1 Signaling Pathway
Oncology Research · 2026 · 34 (7) · 1-10
DOI: 10.32604/or.2026.080621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Lei Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Urological Department, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Shinan District, Qingdao, China. Hauptthemen laut MEDLINE: Sunitinib, Drug Resistance, Neoplasm, Carcinoma, Renal Cell, STAT1 Transcription Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urological Department, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Shinan District, Qingdao, China.
- Urological Department, Qingdao Eighth People's Hospital, No. 84, Fengshan Road, Licang District, Qingdao, China.
Zitieren
APA
Luo, L., Guan, F., Wang, Z., Li, B., Ding, X., Song, L., & Sun, L. (2026). PARP9 Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via STAT1/IRF1 Signaling Pathway. Oncology Research, 34(7), 1-10. https://doi.org/10.32604/or.2026.080621
Vancouver
Luo L, Guan F, Wang Z, Li B, Ding X, Song L, et al. PARP9 Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via STAT1/IRF1 Signaling Pathway. Oncology Research. 2026;34(7):1-10. doi:10.32604/or.2026.080621
BibTeX
@article{Luo2026,
author = {Luo, Lei and Guan, Fengju and Wang, Zhankun and Li, Bin and Ding, Xuemei and Song, Leilei and Sun, Lijiang},
title = {PARP9 Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via STAT1/IRF1 Signaling Pathway},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {7},
pages = {1--10},
doi = {10.32604/or.2026.080621}
}
EUVIMED